Myovant Sciences (MYOV) Given Buy Rating at Cowen

Cowen reaffirmed their buy rating on shares of Myovant Sciences (NYSE:MYOV) in a report issued on Friday.

MYOV has been the subject of several other research reports. Zacks Investment Research raised shares of Myovant Sciences from a sell rating to a hold rating in a research report on Wednesday, October 10th. Goldman Sachs Group started coverage on shares of Myovant Sciences in a research report on Friday, October 26th. They issued a neutral rating and a $25.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Myovant Sciences in a research report on Thursday, September 13th. They issued an overweight rating and a $39.00 price objective for the company. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Myovant Sciences presently has a consensus rating of Buy and a consensus target price of $29.20.

MYOV stock traded down $2.23 on Friday, hitting $19.06. 81,976 shares of the company were exchanged, compared to its average volume of 59,557. Myovant Sciences has a twelve month low of $11.30 and a twelve month high of $27.45. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.07 and a current ratio of 3.07. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -7.91 and a beta of 0.12.

Myovant Sciences (NYSE:MYOV) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.06). As a group, equities analysts forecast that Myovant Sciences will post -3.91 EPS for the current fiscal year.

In other Myovant Sciences news, Director Mark Altmeyer acquired 3,500 shares of the company’s stock in a transaction dated Saturday, November 17th. The stock was bought at an average price of $13.38 per share, with a total value of $46,830.00. Following the completion of the transaction, the director now directly owns 3,500 shares of the company’s stock, valued at $46,830. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.10% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in MYOV. Millennium Management LLC boosted its stake in shares of Myovant Sciences by 79.1% in the second quarter. Millennium Management LLC now owns 191,436 shares of the company’s stock valued at $4,378,000 after purchasing an additional 84,568 shares during the period. Atria Investments LLC purchased a new position in shares of Myovant Sciences in the third quarter valued at $201,000. Janus Henderson Group PLC purchased a new position in shares of Myovant Sciences in the second quarter valued at $25,692,000. Renaissance Technologies LLC purchased a new position in shares of Myovant Sciences in the second quarter valued at $297,000. Finally, Matisse Capital purchased a new position in shares of Myovant Sciences in the second quarter valued at $349,000. 21.04% of the stock is owned by institutional investors.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Story: What Does Beta Mean In Stock Selection

Analyst Recommendations for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply